Foghorn Therapeutics Inc. (FHTX) Stock Profile — Insider Trades & Financials

Revenue$9.2M

Net Income-$21.7M

EPS$-1.18

Market Cap$287.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Adrian H. Gottschalk

CEO & Executive Director

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Founded: 2015
Employees: 106
Headquarters

⚡

Core Efficiency

ROE?

19.97%

ROA?

-10.94%

D/E Ratio?

-2.83

Op. Margin?

-258.22%

📊

Profitability Ratios

Net Margin?

-234.28%

Loading company sections...

Foghorn Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness